- ‘Why can’t women have experience?’ New Bridgerton series tackles sex taboo BBC
- ‘Bridgerton’ season 3 recap: Key storylines to remember before season 4 The Express Tribune
- Bridgerton Season 4, Episode 1 Review: ‘The Waltz’ Fangirlish
Author: admin
-

'Why can't women have experience?' New Bridgerton series tackles sex taboo – BBC
-
In letter to SHC CJ, Sindh governor seeks constitution of judicial commission for Gul Plaza inferno – Dawn
- In letter to SHC CJ, Sindh governor seeks constitution of judicial commission for Gul Plaza inferno Dawn
- Sindh govt announces judicial inquiry into deadly Gul Plaza blaze Dawn
- Pakistan approves compensation as rescue ends 10 days after deadly…
Continue Reading
-

Nicki Minaj expresses support for Trump in public statement
Nicki Minaj has publicly expressed her support for President Donald Trump.
Taking over…
Continue Reading
-
Starmer, Xi signal reset in China-UK ties, eye economic wins – Reuters
- Starmer, Xi signal reset in China-UK ties, eye economic wins Reuters
- Xi-Starmer meeting: Chinese leader tells PM he hopes both countries can ‘rise above differences’ The Guardian
- Chinese President Xi Jinping meets British PM in Beijing
Continue Reading
-

Benazir 8171 Kafaalat 13500 February Payment – Latest Update, Eligibility & How to Check Status
The Benazir 8171 Kafaalat 13500 February payment has brought much needed financial relief for millions of low income families across Pakistan. Under the Benazir Income Support Programme (BISP), eligible women beneficiaries are receiving Rs 13,500…
Continue Reading
-

Exactly When To See The ‘Snow Moon’ Rise
Topline
The full snow moon — the second of 13 full moons in 2026 — will turn full on Sunday, Feb. 1, 2026. Named for the snow on the ground at this time of year in North America, this full moon will rise close to a spectacular star cluster…
Continue Reading
-

Xbox Console Sales Down 32%, Gaming Revenue Drops 9%
As mentioned above, aside from its underperforming gaming division, Microsoft as a whole is experiencing strong growth, reporting Q2 FY 2026 revenue of $81.3 billion, up 17%, and operating income of $38.3 billion, up 21%.
Revenue in the…
Continue Reading
-

King Charles III’s documentary sets out his philosophy for saving the planet
WINDSOR, England — King Charles III is clearly thinking about his legacy.
In his new film, “Finding Harmony: A King’s Vision,” Charles delivers a simple message — that humanity needs to restore the balance between man and nature if it…
Continue Reading
-

Singapore: Regulatory Updates for Therapeutic Product Registration | Insight
In brief
On 16 January 2026, the Health Sciences Authority (HSA) implemented a series of updates on the registration of therapeutic products. The updates are aimed at further improving regulatory efficiency and enhancing clarity for applicants.
In more detail
On 16 January 2026, the HSA released the following key regulatory updates for the registration of therapeutic products:
1. New submission pathway for standard essential medicines
The new submission pathway allows standard essential medicines to be registered through generic drug applications (GDAs). To qualify for this submission pathway, the product must have a well-established safety and efficacy profile, and documented and recognised references. It must not have a corresponding Singapore reference product.
The submission pathway is designed for unregistered medicines that have a long history of local clinical use in Singapore and are critical for Singapore’s healthcare system.
Companies must submit an expression of interest (EOI) form at least three months prior to the intended GDA submission and may only proceed after receiving the HSA’s approval of their EOI.
2. Removal of the limit on concurrent MAV-1 submissions
The HSA has lifted the previous limit of three concurrent major variation applications (MAV-1). This enhancement provides industry stakeholders with greater flexibility in managing post-approval clinical indication expansions and reduces administrative hold-ups.
3. New GMP conformity assessment for overseas DS manufacturing sites
The HSA now permits companies to request that HSA conduct a good manufacturing practice (GMP) inspection for overseas drug substance (DS) manufacturing sites that lack sufficient evidence of GMP compliance when submitting a New Chemical / Biologic Entity (NCE/NBE) registration application.
4. Declaration of conflicts of interest by company-engaged experts
The HSA now requires that any statement of opinion provided by an expert clinician and submitted to support an application be accompanied by a written declaration from the expert clinician confirming that they have no conflict of interest in relation to the application.
Key takeaways
The HSA continues to refine its regulatory processes to ensure that they remain efficient, transparent and aligned with industry needs. These updates will be highly relevant to companies making or planning to make therapeutic product applications in Singapore.
Continue Reading
-

IHC Bar rejects lawyers’ role in Imaan Mazari, husband’s arrests
‘The Bar not only prevented their arrest for two days but also stood firmly with them’
Lawyer duo Imaan Mazari and Hadi Ali Chattha overlooking the Islamabad police stationed outside Islamabad High Court Bar president’s office waiting to arrest…
Continue Reading